EcoVadis Platinum Level Achieved in 2026
We have renewed our EcoVadis assessment and achieved the Platinum level!
Feel the
difference
with HTL inside
Play the video
Meet our
biopolymers
Product Portfolio
Hyaluronic Acid (Sodium Hyaluronate)
Premium Pharma-grade Hyaluronic Acid (Sodium Hyaluronate)
Product Portfolio
Polynucleotides (PDRN - PN)
Premium Pharma-grade Polynucleotides
Product Portfolio
Sodium DNA
Cosmetic grade DNA
Innovation Portfolio
Recombinant Human Collagen III
Discover HTL Biotechnology’s new recombinant human collagen with unique properties.
Innovation Portfolio
Heparosan
Building on the success of Hyaluronic Acid, HTL Biotechnology now wishes to bring new opportunities with Heparosan.
Innovation Portfolio
Oligo HA
Ultra-low molecular weight Hyaluronan.
Our latest news
Articles
April 13, 2026
EcoVadis Platinum Level Achieved in 2026
We have renewed our EcoVadis assessment and achieved the Platinum level!
Articles
March 19, 2026
HTL Biotechnology at PCHi 2026 in Hangzhou
HTL Biotechnology recently took part in PCHi (Personal Care and Homecare Ingredients), one of the leading events for the personal care industry, held in Hangzhou, China.
Articles
February 16, 2026
Lunar New Year 2026: Entering the Year of the Fire Horse
From 17 February, we celebrate the Lunar New Year and step into the Year of the Fire Horse — a powerful symbol of drive, resilience, and forward momentum across Asia.
A time of renewal, ambition, and fresh opportunities for growth.
Articles
February 1, 2026
HTL Biotechnology at IMCAS 2026: advancing the future of regenerative medicine
HTL Biotechnology took part in IMCAS 2026, one of the leading international congresses dedicated to aesthetic medicine and dermatology. This major event was an opportunity to highlight the company’s strategy, innovations, and commitment to advancing regenerative medicine through high-performance biopolymers.
Feel the difference with HTL inside
Feel the difference with HTL inside
We Are Worldwide
A global company with a heart in Brittany
HTL Biotechnology is the pioneer in the development and sustainable production of pharmaceutical grade biopolymers, used to develop life-changing treatments for millions of patients worldwide.
Backed by 45 years of expertise, we now work with more than 100 clients in 30 countries. In total, over 500 million syringes of hyaluronic acid have been safely used since 2006.
45 Years of expertise
100+ clients
30 countries of export
500+ million syringes safely used since 2006
A trusted partner
As the market leader in pharmaceutical grade biopolymers for medical use, we work every day to :
- Provide its customers with high-quality products ;
- Ensure the health, safety and well-being of its employees ;
- Control the environmental impact of its activities ;
- Innovate in an ethical and responsible manner with its customers, suppliers and other partners.
